Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finolimab plus TP neoadjuvant therapy with response-driven stratified treatment for laryngeal preservation
ChiCTR2600130836Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of finolimab in laryngeal squamous cell carcinoma (LSCC) and squamous cell carcinoma of the hypopharynx, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 2-year Laryngeal Preservation Survival rate (2-LPS). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
finolimab
03
Conditions
laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on ChiCTR2600130836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130836.